.jpg)
.png)
Last Updated: Friday, 31-May-2024 15:00:00 EDT
National Lipid Association Unveils New Mission to Advance Lipidology and Cardiometabolic Health
JACKSONVILLE, Fla. – (May 31, 2024) - The National Lipid Association (NLA) is proud to announce its renewed mission: “To enhance the science and practice of lipidology and promote optimal cardiometabolic health.” This updated mission underscores the NLA’s commitment to advancing the field of lipidology and improving health outcomes for individuals with lipid disorders.
Last Updated: Wednesday, 29-May-2024 22:00:00 EDT
Arrowhead Pharmaceuticals is proud to announce the publication of two back-to-back NEJM manuscripts in the mixed hyperlipidemia population with plozasiran (MUIR study with APOC3 target) and zodasiran (ARCHES2 study with ANGPTL3 target) following the EAS presentations by Drs. Ballantyne and Rosenson.
The press releases with manuscript information can be accessed here.
Founding Member of the Northeast Lipid Association
A physician’s physician
A true patient advocate
Mentor
Friend
Article By:
National Lipid Association
It is an honor to contribute this PLA Chapter Update to the current edition of LipidSpin. Congratulations to all PLA and SWLA authors who contributed to this edition. We sincerely appreciate the time and effort involved, and we are also grateful for the mentorship provided by senior authors to individuals who may be newer to the field of clinical lipidology. LipidSpin is such a critical part of the NLA’s efforts to help educate and generate excitement around the field of lipidology!
Article By:
Michael Wilkinson, MD, FACC, FNLA*
President-Elect, Pacific Lipid Association
Assistant Professor
Division of Cardiovascular Medicine
UC San Diego
San Diego, CA
There has been robust participation among SWLA members in the National Lipid Association activities and outstanding contributions to the field of lipidology! Here are just a few highlights of what our productive group achieved in 2023!
Article By:
Anandita Kulkarni, MD, FACC
Secretary, Southwest Lipid Association
Clinical Assistant Professor, Texas A&M University College of Medicine
Center for Cardiovascular Disease Prevention
Baylor Scott & White Health- The Heart Hospital Baylor Plano
Plano, TX
Introduction
The association of statin use, and incident type 2 diabetes (T2D) is well established in adults.1 Similar observations have not been reported in youth. Despite this association, the benefits of statins in preventing atherosclerotic cardiovascular disease (ASCVD) appear to outweigh their adverse effects on glycemic control.
Case #1
Article By:
Gabriella E. Webster, MS
Baylor Scott & White Health
Texas A&M University Health Science Center
Dallas, TX
Amelia Vinson, RN
Pediatric Endocrinology and Diabetes
Cook Children’s Medical Center
Fort Worth, TX
Luke Hamilton, MS
Pediatric Endocrinology and Diabetes
Cook Children’s Medical Center
Fort Worth, TX
Don Wilson, MD, FNLA*
Pediatric Endocrinology and Diabetes
Cook Children’s Medical Center
Fort Worth, TX
Key points
Article By:
Pamela L. Alebna, MD, MPH
Cardiovascular Disease Fellow
Pauley Heart Center
Virginia Commonwealth University
Richmond, VA
Leonid Khokhlov, MD
Chief Internal Medicine Resident
TriHealth, Good Samaritan Hospital
Cincinnati, OH
Anurag Mehta, MD, FACC
Director, Preventive Cardiology
Pauley Heart Center
Assistant Professor, Internal Medicine
Virginia Commonwealth University School of Medicine
Richmond, VA
Introduction
Article By:
Mariana L. Henry, MPH
NLA Women’s Health Group
Dartmouth Geisel School of Medicine
Hanover, NH
Pamela Papp, APRN, C-NP, FNLA
NLA Women’s Health Group
Northwestern Medicine
Winfield, IL
Robert Wild MD, PhD, FNLA
NLA Women’s Health Group
Department of Obstetrics and Gynecology
Oklahoma University Health Sciences Center
Oklahoma City, OK
Eliot A. Brinton MD, FAHA, FNLA, FACE
NLA Women’s Health Group
Utah Lipid Center
Family and Preventive Medicine
University of Utah
Salt Lake City, UT
Merle Myerson MD, EdD, FACC, FNLA
NLA Women’s Health Group
Etna, NH
Introduction
Article By:
Usman Sagheer, MD
Division of Cardiology
Department of Medicine
University of Louisville
Louisville, KY
Dinesh K. Kalra, MD FACC, FSCCT, FSCMR, FNLA
Division of Cardiology
Department of Medicine
University of Louisville
Louisville, KY
Dyslipidemia frequently presents in individuals with thyroid dysfunction, attributed to the influence of thyroid hormones on various key metabolic pathways, thereby contributing to an elevated cardiovascular (CV) risk.1 In this discussion, we delve into the intricate connection between thyroid dysfunction and lipid metabolism, providing recommendations for effective surveillance and management.
Overview of Thyroid Dysfunction
Article By:
Nirmita Doshi, MD
Department of Medicine
Alameda Health System
Oakland, CA
Safa Aldabyani, MD
Department of Medicine
Alameda Health System
Oakland, CA
Aman Rajpal, MD, DABOM
Department of Medicine
Alameda Health System
Oakland, CA